Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Entrada Therapeutics is raising $59,021,750.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Dipal Doshi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Entrada Therapeutics

Entrada Therapeutics’ mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada’s technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company’s novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol.

To learn more about Entrada Therapeutics, visit http://www.entradatx.com/

Contact:
Dipal Doshi, President and Chief Executive Officer
857-305-1825
https://www.linkedin.com/in/dipal-doshi-85892/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved